Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.
Picod A, Rebibou JM, Dossier A, Cador B, Ribes D, Vasco-Moynet C, Stephan C, Bellal M, Wynckel A, Poullin P, Péju E, Ricard L, Kahn JE, Bouzid R, Benhamou Y, Joly B, Veyradier A, Coppo P. Picod A, et al. Among authors: poullin p. Blood. 2022 Apr 21;139(16):2565-2569. doi: 10.1182/blood.2021015149. Blood. 2022. PMID: 35271696 Free PMC article. No abstract available.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.
Hie M, Gay J, Galicier L, Provôt F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Centre. Hie M, et al. Among authors: poullin p. Blood. 2014 Jul 10;124(2):204-10. doi: 10.1182/blood-2014-01-550244. Epub 2014 May 28. Blood. 2014. PMID: 24869941 Free article.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, Hié M, Presne C, Poullin P, Wynckel A, Saheb S, Deligny C, Servais A, Girault S, Delmas Y, Kanouni T, Lautrette A, Chauveau D, Mousson C, Perez P, Halimi JM, Charvet-Rumpler A, Hamidou M, Cathébras P, Vanhoorelbeke K, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Center. Jestin M, et al. Among authors: poullin p. Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10. Blood. 2018. PMID: 30201758 Free article.
Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Prevel R, Roubaud-Baudron C, Gourlain S, Jamme M, Peres K, Benhamou Y, Galicier L, Azoulay E, Poullin P, Provôt F, Maury E, Presne C, Hamidou M, Saheb S, Wynckel A, Servais A, Girault S, Delmas Y, Chatelet V, Augusto JF, Mousson C, Perez P, Halimi JM, Kanouni T, Lautrette A, Charvet-Rumpler A, Deligny C, Chauveau D, Veyradier A, Coppo P. Prevel R, et al. Among authors: poullin p. Blood. 2019 Dec 12;134(24):2209-2217. doi: 10.1182/blood.2019000748. Blood. 2019. PMID: 31530564 Free article.
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y. Coppo P, et al. Among authors: poullin p. Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021. Blood. 2021. PMID: 33150928 Free PMC article.
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP. Fakhouri F, et al. Among authors: poullin p. Blood. 2005 Sep 15;106(6):1932-7. doi: 10.1182/blood-2005-03-0848. Epub 2005 Jun 2. Blood. 2005. PMID: 15933059 Free article. Clinical Trial.
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P; Thrombotic Microangiopathies Reference Center. Benhamou Y, et al. Among authors: poullin p. Haematologica. 2012 Aug;97(8):1181-6. doi: 10.3324/haematol.2011.049676. Epub 2012 May 11. Haematologica. 2012. PMID: 22580997 Free PMC article.
Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center.
Benhamou Y, Baudel JL, Wynckel A, Galicier L, Azoulay E, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Halimi JM, Rivière E, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Chauveau D, Veyradier A, Coppo P. Benhamou Y, et al. Among authors: poullin p. Am J Hematol. 2015 Jun;90(6):E127-9. doi: 10.1002/ajh.23997. Am J Hematol. 2015. PMID: 25740210 Free article. No abstract available.
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.
Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, Baudel JL, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Chauveau D, Veyradier A, Halimi JM, Hamidou M, Coppo P; French Thrombotic Microangiopathies Reference Center. Roriz M, et al. Among authors: poullin p. Medicine (Baltimore). 2015 Oct;94(42):e1598. doi: 10.1097/MD.0000000000001598. Medicine (Baltimore). 2015. PMID: 26496263 Free PMC article.
72 results